Key result
Each interquartile range increase in baseline plasma MeFOSAA concentration was associated with a 16% higher risk of major adverse cardiovascular events (HR 1.16; 95% CI 1.01-1.33).
Why the study?
Do higher baseline plasma concentrations of PFAS predict incident cardiovascular disease in adults with prediabetes?
Cohort (n=1,382)
Do higher baseline plasma concentrations of PFAS predict incident cardiovascular disease in adults with prediabetes?
Higher plasma concentrations of select PFAS, particularly MeFOSAA, are associated with increased risk of MACE and CVD death in adults with prediabetes.
Background: Per- and polyfluoroalkyl substances (PFAS) are persistent environmental contaminants linked to cardiometabolic dysfunction, yet their prospective association with cardiovascular disease (CVD) in high-risk populations remains unclear. We evaluated whether baseline plasma PFAS concentrations predict incident CVD in adults with prediabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Methods: In 1,382 DPPOS participants, we measured baseline plasma concentrations of six PFAS (PFHxS, PFOS, PFOA, PFNA, MeFOSAA, EtFOSAA). Notably, MeFOSAA and EtFOSAA eventually metabolize to PFOS. We followed participants for a median of 21 years. Cox proportional hazards models estimated risks for CVD per interquartile range (IQR) increase in PFAS. We assessed PFAS mixture effects using a burden score and quantile g-computation and explored effect modification by age, sex/menopause, diet, and physical activity. Data provided by NIDDK CR, a program of the National Institute of Diabetes and Digestive and Kidney Diseases. Results: At baseline (1996-1999, mean [SD] age 52.1 [10.3] years), median PFAS concentrations were comparable to U.S. reference values (e.g., PFOS: 27.9 ng/mL; PFOA: 4.77 ng/mL). Incidence of major adverse cardiovascular events (MACE) was 9.6%; CVD death was 3.9%. Each IQR (1.1 ng/mL) increase in MeFOSAA was associated with a 16% higher risk of MACE (95% CI: 1.01–1.33) and 24% higher CVD death risk (95% CI: 1.02–1.52). PFHxS, PFOS, EtFOSAA, and PFOA were linked to elevated risks of non-fatal myocardial infarction, hospitalized congestive heart failure, and CVD death. Mixture and total PFAS burden analyses showed no significant associations. No consistent effect modification was observed by age, sex, diet, or physical activity. Sensitivity analyses accounting for additional covariates, including educational attainment, martial status, alcohol intake, physical activity, BMI, and fish intake, showed consistent results. Conclusion: Higher plasma concentrations of select PFAS, particularly MeFOSAA, were associated with increased CVD risk in adults with prediabetes, independent of lifestyle factors. These findings highlight PFAS as potential environmental contributors to CVD in metabolically vulnerable populations, warranting further investigation and clinical consideration.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) conducted a cohort in Prediabetes (n=1,382). Plasma PFAS concentrations (particularly MeFOSAA) vs. Lower PFAS concentrations (per IQR increase) was evaluated on Major adverse cardiovascular events (MACE) (HR 1.16, 95% CI 1.01-1.33). Each interquartile range increase in baseline plasma MeFOSAA concentration was associated with a 16% higher risk of major adverse cardiovascular events (HR 1.16; 95% CI 1.01-1.33).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: